Daily Rules, Proposed Rules, and Notices of the Federal Government
Transcripts of the public hearing will be available for review at the Division of Dockets Management and on the Internet at
A live Web cast of this public hearing may be seen at
FDA is announcing a 1-day public hearing to obtain input on certain questions related to the implementation of section 918 of the FD&C Act (21 U.S.C. 387r), as amended by the Tobacco Control Act (Pub. L. 111-31). Section 918 has two parts. Under Section 918(a), which is primarily focused on NRTs, the Secretary of the Department of Health and Human Services (the Secretary of HHS) is required to consider certain new approval mechanisms and additional indications for NRTs. Several NRTs, including nicotine-containing gums, patches, and lozenges, are already marketed for smoking cessation. Under section 918(b), a broader range of products is implicated. Section 918(b) requires that the Secretary of HHS, after consultation with recognized scientific, medical, and public health experts, submit a report to Congress examining how best to regulate, promote, and encourage the development of “innovative products and treatments (including nicotine-based and non-nicotine-based products and treatments)” to better achieve the following three goals: (1) Total abstinence from tobacco use, (2) reductions in consumption of tobacco, and (3) reductions in the harm associated with continued tobacco use. The purpose of this public hearing is to create a forum for interested stakeholders to provide input regarding FDA's fulfillment of the requirements set forth in section 918, including on the following issues, among others: (1) The use of fast-track and accelerated approval authorities for smoking-cessation products, including NRTs; (2) the potential for extended use of NRTs (beyond currently approved durations of use) for the treatment of tobacco dependence; (3) the potential for additional indications for NRTs, including for craving relief or relapse prevention; and (4) how best to regulate “innovative products and treatments” targeted at tobacco users in order to achieve abstinence from tobacco use, reductions in consumption of tobacco, and reductions in the harm associated with continued tobacco use. FDA will consider the information it obtains from the public hearing in its implementation of the requirements of section 918, including in drafting the report to Congress required by section 918(b).
The purpose of this 21 CFR part 15 hearing is to receive information and comments from a broad group of stakeholders, including manufacturers, interested industry and professional organizations, the public health community, individuals affected by tobacco dependence, researchers, health care professionals, and the public, regarding implementation of section 918 of the FD&C Act. FDA is also consulting directly with other Federal agencies and third parties, as contemplated by section 918.
FDA is particularly interested in obtaining information and public comment on the issues listed in sections II.A and II.B of this document, although comments related to any issues regarding implementation of section 918 are welcome.
Fast-Track Status for Smoking-Cessation Products, Including NRTs.
Section 918(a)(1) of the FD&C Act provides that the Secretary of HHS must, “at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of section 506” of the FD&C Act (21 U.S.C. 356).
Accelerated approval and fast track designation are available under section 506 of the FD&C Act and FDA regulations,
FDA seeks comment on the following issues related to section 918(a)(1) of the FD&C Act:
1.1. How can FDA best use its authorities under section 506 of the FD&C Act, as amended by FDASIA (including the designation of products as “fast track products” and as “breakthrough therapies”), to facilitate expedited review and accelerated
1.2. Under what circumstances should a smoking-cessation product candidate be considered to fill an unmet medical need under section 506, in light of the existing products for smoking cessation?
1.3. What kind of preliminary clinical evidence might support the designation of a smoking-cessation product candidate as a “breakthrough therapy” under section 506?
On October 26 and 27, 2010, FDA held a public workshop entitled “Risks and Benefits of Long-Term Use of Nicotine Replacement Therapy Products.” The questions explored in that workshop overlap with the issues raised in section 918(a)(2) of the FD&C Act. Although FDA does not seek to duplicate the discussion held at the October 2010 workshop, FDA is interested in receiving any new or additional information that might be relevant to the extended use of NRTs for tobacco dependence.
FDA seeks comment on the following issues related to section 918(a)(2) of the FD&C Act:
2.1. What evidence is available to support the approval of NRTs for extended use to maintain abstinence in individuals who have quit?
2.2. What evidence is available to support the approval of NRTs for extended use to achieve cessation (quitting)?
2.3. With regard to both of the above indications, does the evidence implicate specific populations?
FDA seeks comment on the following issues related to section 918(a)(3) of the FD&C Act:
3.1. If an additional indication is sought for an approved NRT in which craving relief itself is the endpoint of efficacy studies:
a. How can the concept of “craving” be adequately characterized to support a potential indication for craving relief?
b. Craving can occur in the context of acute withdrawal or long after a former smoker has quit (the latter may be described as “provoked” or “cue-induced” craving). Have both types of craving been adequately characterized to support a potential indication for craving relief?
c. Are there scientifically acceptable study designs for establishing efficacy for craving relief that use:
i. Established instruments to measure patient-reported outcomes?
ii. Analytical methods that address the degree of craving relief that should be considered clinically significant?
3.2. If an additional indication is sought for an approved NRT for relapse prevention:
a. How should “relapse” be defined and measured?
b. How should the population of individuals at risk of relapse be defined?
3.3. Are there other additional indications that might be sought for approved NRT products?
Section 918(b) of the FD&C Act requires that the Secretary of HHS, after consultation with recognized scientific, medical, and public health experts, submit to Congress a report that examines how best to regulate, promote, and encourage the development of “innovative products and treatments (including nicotine-based and non-nicotine-based products and treatments) to better achieve, in a manner that best protects and promotes the public health—(A) total abstinence from tobacco use; (B) reductions in consumption of tobacco; and (C) reductions in the harm associated with continued tobacco use.” The report to Congress must include the recommendations of the Secretary of HHS on how FDA should coordinate and facilitate the exchange of information on these “innovative products and treatments” among relevant offices and Centers within FDA and within the National Institutes of Health, the Centers for Disease Control and Prevention, and other relevant Agencies such as the Substance Abuse and Mental Health Services Administration.
One question raised by section 918(b) of the FD&C Act is how FDA should regulate specific “innovative products and treatments” that make claims in the three categories identified. “Abstinence from tobacco use” may be understood to include non-initiation of tobacco use (never starting to use) as well as cessation of tobacco use (a user successfully quitting). Product claims in this category might therefore include claims to prevent or inhibit initiation as well as claims to bring about cessation.
A claim to reduce consumption of tobacco might, for example, suggest that the product would cause users to smoke fewer cigarettes or otherwise consume less tobacco. A claim to reduce the harms associated with continued tobacco use might, for example, suggest that the user could continue consuming tobacco as desired without experiencing one or more of the harmful effects of tobacco use.
Section 918(b) also raises a question as to how FDA and other HHS Agencies can implement regulation and policy with regard to the “innovative products and treatments” referenced in the statute to bring about the three effects identified—abstinence, reductions in consumption, and reductions in the harm associated with continued use—as broader outcomes, in a manner that best protects and promotes the public health.
FDA seeks comment on the following issues related to these provisions of section 918(b):
4.1. What kinds of innovative products and treatments designed to achieve any of the above three purposes—abstinence from tobacco use, reduction in tobacco consumption, and reduction in the harm associated with continued use—might be developed to meet the criteria for marketing under applicable legal authorities?
4.2. With regard to the “abstinence” category, what innovative products and treatments might be developed to better achieve either cessation or non-initiation? What are the established methods for measuring the prevention or inhibition of initiation?
4.3. With regard to innovative products and treatments for “reduction in consumption of tobacco,”
a. How can the reduction best be measured?
b. If the reduction is associated with a certain goal or benefit:
i. What evidence is available to indicate that the reduction in consumption will bring about that goal or achieve that benefit?
ii. What degree and duration of reduction are necessary to achieve that goal or benefit?
4.4. With regard to innovative products and treatments for “reduction in the harm associated with continued tobacco use”:
a. How should the “harm” be identified and measured?
b. Is there a range of harms that might be addressed, and if so, which are the most important to address?
4.5. With regard to innovative products and treatments making claims in any of the three categories identified in section 918(b), what barriers exist to development and marketing approval?
4.6 In regulating the innovative products and treatments referenced in section 918(b), how can FDA and other HHS Agencies act to ensure that the three effects mentioned in section 918(b)—total abstinence from tobacco use, reductions in consumption of tobacco, and reductions in the harm associated with continued tobacco use—are achieved as broader outcomes, in a manner that best protects and promotes the public health?
4.7. How can these broader outcomes be taken into account in FDA's premarket evaluation of new product candidates?
The FDA Conference Center at the White Oak location is a Federal facility with security procedures and limited seating. Attendance is free and will be on a first-come, first-served basis. Individuals who wish to present at the public hearing must register by December 6, 2012, and provide complete contact information, including name, title, affiliation, address, email, and phone number. Those without email access may register by contacting Ayanna Augustus (see
If you need special accommodations because of a disability, please contact Ayanna Augustus (see
A live Web cast of this public hearing may be seen at
The Commissioner of Food and Drugs is announcing that the public hearing will be held in accordance with part 15 (21 CFR part 15). The hearing will be conducted by a presiding officer, who will be accompanied by senior management and technical experts from various offices within FDA.
Under § 15.30(f), the hearing is informal and the rules of evidence do not apply. No participant may interrupt the presentation of another participant. Only the presiding officer and panel members may question any person during or at the conclusion of each presentation. Public hearings under part 15 are subject to FDA's policy and procedures for electronic media coverage of FDA's public administrative proceedings (part 10 (21 CFR part 10, subpart C)). Under § 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants. The hearing will be transcribed as stipulated in § 15.30(b) (see section VI of this document). To the extent that the conditions for the hearing, as described in this document, conflict with any provisions set out in part 15, this document acts as a waiver of those provisions as specified in § 15.30(h).
Regardless of attendance at the public hearing, interested persons may submit either electronic or written comments to the Division of Dockets Management (see
Transcripts of the public hearing will be available for review at the Division of Dockets Management (see